Targeted drug trial aims to control tough cancers with specific genetic flaw
NCT ID NCT06360588
Summary
This study is testing whether the drug copanlisib can help control advanced cancers that have lost a specific protein called PTEN. The trial includes 22 patients with various solid tumors that have stopped responding to standard treatments. Researchers are giving the drug through an IV to see if it can shrink tumors or slow their growth by blocking enzymes cancer cells need to survive.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.